Though efforts to identify the genetic etiology of Alzheimer disease (AD) have made substantial progress, to date only some of the genes contributing to AD risk have been identified. Utilization of more etiologically homogeneous subphenotypes represents one strategy to facilitate the identification of novel risk genes in complex disorders. In this review, we evaluate the hypothesis that psychotic symptoms, such as delusions and hallucinations, define a suitable subphenotype in AD patients for gene-mapping efforts. Psychotic symptoms occur in 40-60% of patients with AD and are associated with more severe cognitive deficits and a more rapidly deteriorating course. The presence of psychotic symptoms in AD confers increased risk of similar symptoms to affected siblings. Candidate gene association analyses and initial linkage analysis have yielded significant results. We discuss possible genetic models of psychotic symptoms in AD, and suggest strategies for further investigation. Identification of such genetic factors may facilitate gene-mapping studies for both AD and idiopathic psychoses. 
Overview
The genetic basis of Alzheimer disease (AD) is unknown, although considerable strides have been made using gene-mapping efforts. Success has been most notable for the highly heritable early onset form, which comprises a minority of the entire population of AD cases. 1 While the impact of apolipoprotein E e4 alleles (APOE4) is well established, the genetic architecture of the more common late-onset AD (LOAD) is unclear. Like other genetically complex disorders, such as diabetes mellitus, progressively greater attention has been paid to utilizing defined subgroups of AD (eg late age-of-onset, APOE4 presence, autopsy confirmation) for mapping liability genes. 2, 3 We have previously proposed that the presence of psychotic symptoms, delusions and hallucinations, define a subgroup of AD 4 that may be suitable for genetic investigation. 5, 6 To our knowledge, however, the available evidence pertaining to whether AD with psychosis (AD þ psychosis (AD þ P)) identifies a phenotype suitable for genetic study has not been the subject of critical review.
Stedman's Medical Dictionary defines phenotype as 'the observable characteristics, at the physical, morphologic, or biochemical level, of an individual, as determined by the genotype and environment'. 7 The genes associated with a behavioral phenotype, however, are unknown. The task for the psychiatric geneticist, therefore, is to identify a behavioral phenotype that varies according to alleles at a restricted set of genes. As in all psychiatric nosology, a behavioral phenotype must be readily and reliably identifiable in all patients of interest. If this behavioral phenotype has clinical relevance (eg bipolar illness) it provides a measure of face validity, and adds significance to its use in the search for causative genes. Tsuang et al. 8 enumerated additional criteria for determining that a behavioral phenotype has a substantial genetic basis, including state independence, biological specificity, familial aggregation, heritability, and cosegregation. This review will examine whether AD þ P represents a reliably identifiable, clinically relevant behavioral phenotype. Using the criteria above as a guide, we will summarize the available data informing the extent to which AD þ P is a valid indicator of a behavioral phenotype for genetic study. We will discuss possible models of AD þ P and examine the available evidence from existing genetic studies of AD þ P. Finally, we suggest strategies for future investigation.
Evidence for a distinct phenotype
Reliability of diagnosis of AD þ P The definition of psychotic symptoms in AD has generally been limited to the presence of delusions and hallucinations. In the absence of delusions and hallucinations, disorganized thought processes are attributed to the cognitive impairments of AD, and not taken to represent a 'thought disorder' indicating a superimposed psychotic syndrome. A wide variety of delusions have been reported in AD, including delusions of persecution, delusions of infidelity, delusions of abandonment, or delusions that deceased individuals (eg parents) are still living. 9 In addition to these delusions, a set of misidentification delusions are frequent in AD patients: belief that one's home is not one's home; belief that a family member is someone else, has been reduplicated or is an imposter; belief in the presence of phantom boarders; and, the belief that images on the television are actually people present in the house. 10 Hallucinations in AD can occur in any sensory modality, but visual and auditory hallucinations are most common. 9 Determining that an individual with AD is in fact delusional can be clinically challenging. Many of the above delusions (eg theft, infidelity, abandonment) can represent accurate interpretations of real events. Care must be taken to exclude this possibility. Certain delusional ideas must be distinguished from simple forgetting. Several accessory qualities of the idea need to be assessed to make this differentiation. Was the information ever encoded in memory? A patient with moderate or severe AD is unlikely to sustain memory of an event that occurs while in this stage (eg that a parent recently died). Some individuals will confabulate responses in the absence of memory for events. In these cases, additional characteristics of the idea, such as whether the individual accepts reality testing and the persistence of the idea over time, are useful in distinguishing delusions. Devanand et al 11 proposed broad and narrow definitions of a delusion. A broad delusion was a false idea for which the individual does not accept reality testing. The narrow definition further required the idea to be persistent or recurrent over time. This narrow definition has been more generally adopted, though no clear consensus on the duration required exists, with criteria ranging from more than two to three episodes in a week, 5, 11 to repeated episodes persistent for at least 7 days, 12, 13 to repeated episodes persistent for at least 1 month. 4 Determining the presence of hallucinations in AD patients presents different challenges. Since many AD subjects have expressive language difficulties, it may not be clear whether they are indeed hallucinating or experiencing illusions. Nocturnal hallucinations present another challenge. Hallucinations transiently occurring upon falling asleep or awakening can be normal phenomena, but it may not be possible to make this distinction in an AD patient. Finally, care must be taken to exclude the possibility that hallucinations (and delusions) were not solely limited to a period of acute delirium, or a transient, medicationinduced state. 4 Despite the need for significant clinical judgment in the identification of psychotic symptoms in AD, most evidence indicates that this attribution can be made reliably. A variety of rating scales have been developed for the identification of psychotic symptoms in AD, and scoring of their severity. 9, [14] [15] [16] When interrater reliability for measuring the severity of individual psychotic symptoms on these scales has been assessed, it has generally been high. 9, 16, 17 In contrast, little data are available to inform whether a classification of an individual as having AD þ P can be achieved reliably. Jeste and Finkel indicated that their proposed diagnostic criteria for AD þ P could be reliably applied, 4 though no supporting data were presented. One of us (RAS) recently examined the inter-rater and test-retest reliability of classifying AD subjects as AD þ P after a caregiver interview with the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Behavior Rating Scale. 9 Inter-rater reliability among 17 psychiatrists and psychiatric social workers showed near-perfect agreement for the classification of AD þ P, with kappa's ranging from 0.8 to 1.0. Test-retest reliability was assessed by conducting a telephone interview, within 1 week preceding or following a face-to-face evaluation by a second clinician. Test-retest kappa's were in perfect agreement, 1.0, for the presence of AD þ P (unpublished observations).
Clinical significance of AD þ P The clinical significance of identification of psychotic symptoms in AD subjects cannot be overstated. First and foremost, psychotic symptoms occur in a substantial proportion of AD patients. Estimates of psychosis prevalence in AD patients range from 10 to 73%, with most studies finding prevalences of 30 to 40%. 18 A recent report identified a 3-year cumulative incidence of AD þ P of 51%. 19 Post-mortem studies, which have the potential advantage of recording a complete cumulative incidence of AD þ P, have similarly reported rates of approximately 40-60%. [20] [21] [22] However, all of the studies described above have conducted either cross-sectional assessment for AD þ P, or longitudinal assessments with a limited duration of follow-up. Better estimates of the rate of AD þ P could be obtained by thorough longitudinal assessments of subjects through their course of illness.
When present, psychotic symptoms can cause significant distress for the patient experiencing them. AD þ P is similarly associated with significant distress to family members providing care to these patients. 23 There is also evidence for a significant association between AD þ P and the development of aggressive behaviors. Deutsch et al 24 reported that 40% of AD subjects with delusions, 42% of AD subjects with misidentification delusions, and 42% of AD subjects with hallucinations also experienced episodes of physical aggression. Aarsland et al 25 found hallucinations to be associated with an increased risk of physical and verbal aggression. In the largest of these cross-sectional studies, Sweet et al 26 found aggression to be significantly associated with AD þ P in 332 AD subjects. The odds ratio (95% confidence interval) for aggression in AD þ P was 6.4 (3.8,10.8) . Two recent studies have also examined whether current psychotic symptoms are predictive of later aggressive behavior. 27, 28 Gilley et al 27 found delusions to be strongly predictive of subsequent physical aggression during 1 year of weekly follow-up of 270 probable AD subjects. In contrast, McShane et al 28 did not find a relationship between delusions and later aggression, but did find that hallucinations predicted physical aggression during 4 years of follow-up. Reflecting the contribution of AD þ P to patient distress and its comorbidity with aggressive behavior, psychotic symptoms in AD are a frequent indication for pharmacotherapy, 29 though AD þ P subjects typically require lower antipsychotic doses than elderly patients with idiopathic psychoses. 4 Perhaps less clinically dramatic than its association with aggressive behaviors, most evidence indicates that AD þ P is a marker for more severe cognitive impairments. AD þ P has been associated with more severe cognitive and functional deficits in AD subjects matched on other clinical characteristics. [30] [31] [32] [33] [34] Studies conflict regarding whether AD þ P is associated with more rapid cognitive deterioration, though most have found an association. 19, [35] [36] [37] [38] It should be noted that most of these studies have not controlled for the duration of AD prior to study entry. In McShane et al, 39 however, the significant association between psychosis and rate of cognitive decline remained when duration of AD was entered into the regression model. Similarly, Drevets and Rubin 35 found more rapid cognitive decline in AD þ P subjects, despite their having a mean duration of AD that did not differ from the nonpsychotic AD subjects. Importantly, Paulsen et al found evidence of more rapid cognitive deterioration preceding the symptomatic onset of psychosis. 19 Rate of decline in semantic fluency and in global cognition as measured by the Mattis Dementia Rating Scale were both strongly predictive of psychosis onset within the subsequent year. Thus, more rapid cognitive deterioration in AD þ P is unlikely to be solely an artefact of neuroleptic medication use. 39 Reflecting the association between psychosis and cognitive deterioration in subjects with AD, the presence of psychotic symptoms is also an independent predictor of more rapid functional decline. 35, 36 Finally, whether due to excess cognitive and functional impairment, or due to caregiver burden and aggressive behavior, 40 AD þ P is a predictor of premature institutionalization. 36, 41 Whether the association between AD þ P and more rapid cognitive and functional deterioration could be mediated by inadvertent over-representation of individuals with Dementia with Lewy Bodies (DLBs) in the more rapidly deteriorating AD þ P group is an important consideration. Well-formed visual hallucinations are among the core diagnostic features of (DLBs), and delusions are an accessory diagnostic feature. 42 Current antemortem diagnostic criteria for DLBs may have low sensitivity and specificity for discriminating between AD and DLBs in mild-tomoderate illness, rendering it likely that clinically defined AD cohorts will contain a modest proportion of DLB subjects. 43 Some studies have indicated that post-mortem verified DLB subjects may have a faster rate of cognitive decline than AD subjects. 44, 45 In contrast, other studies have not found post-mortemverified DLBs to be associated with faster cognitive decline, or with psychosis. 43, 46 Even if DLB does account for some of the association between rate of cognitive decline and presence of psychotic symptoms, it is unclear whether the proportion of DLB subjects included in studies of cognitive decline in AD þ P would be sufficient to account for the entire effect. Moreover, conclusions about the inter-relationships between AD, DLBs, presence of psychotic symptoms, and rate of cognitive decline based on studies conducted to date must be considered tentative. Understanding of the relationship between AD and DLBs is rapidly evolving. The use of new more sensitive antialphasynuclein immunocytochemical staining has revealed that Lewy Body pathology may be more common than previously suspected in AD, 47 rendering less certain the proper interpretation of studies which identified post-mortem evidence of Lewy Bodies using immunocytochemical and histochemical methods which may only identify more severe Lewy Body pathology.
State independence of AD þ P As applied to AD þ P, state independence would require psychotic symptoms to be persistent within individuals with AD over the course of illness. A number of studies have examined this question. 37, [48] [49] [50] [51] These studies ranged in duration of follow-up from 6 months to 5 years, and used different methods of behavioral assessment and different data analytic approaches. Nevertheless, all found either the presence of AD þ P, or the severity of psychotic symptoms, to be at least moderately persistent over time. Thus, Devanand et al 48 found the 6-month probability of persistence of delusions and hallucinations to be 0.59 and 0.52, respectively. Levy et al 37 found that the 1-year recurrence rate of AD þ P was 95%.
Biologic specificity of AD þ P The finding of a combined liability to psychotic symptoms and excess cognitive impairment in AD raises the question of biologic specificity. That is, does AD þ P arise merely as an epiphenomenon of more severe stage of illness, or is there a distinct pathology underlying both the generation of psychotic symptoms and the excess cognitive impairment? This question is informed by clinical, neuroimaging, neuropathologic, and genetic studies.
There is fairly consistent evidence that psychotic symptoms are rare as a prodrome of AD, and infrequent in the early stages of illness. 52, 53 AD þ P prevalence increases as the illness progresses from the mild-to-moderate stages of AD. [35] [36] [37] 48, 50, 53 As patients progress to late stage illness, stable, higher, and lower AD þ P prevalences have been described. [35] [36] [37] 48, 50, 53 These data might suggest that AD þ P is a nonspecific concomitant of more severe disease. However, several clinical findings argue against this interpretation. First, AD þ P is not an invariant component of progression to later disease stages. The cumulative incidence of AD þ P is only 40-60% of all AD cases. [19] [20] [21] [22] Second, AD þ P is associated with excess cognitive burden in AD subjects matched on other clinical variables, including dementia duration. 31, 33 Third, AD þ P is not only associated with increased cognitive impairment, but with a more rapid rate of cognitive deterioration. 19, 35, 37, 38 In the only study to examine cognitive decline prior to psychosis onset, the increased rate of cognitive decline preceded psychosis onset. 19 While the association between AD þ P and more rapid cognitive deterioration could suggest that it is the rate of cognitive decline which identifies the true phenotype of interest, evidence from other disorders, for example, schizophrenia and major depression, that psychosis is inextricably linked to cognitive impairment, 54 supports the interpretation that AD þ P and excess cognitive burden arise from the same underlying mechanism. 55 The clinical observation that AD þ P was associated with more severe cognitive pathology also led investigators to examine whether AD þ P was correlated with evidence of more severe AD neuropathology in specific brain regions. Several early studies reported varying results: increased area density of senile plaques in prosubiculum, 56 increased area density of neuritic plaques averaged across neocortical and medial temporal brain regions, 57 or no change in area density of senile plaques. 22 Similarly with regard to neurofibrillary tangles, either increased area density in middle frontal cortex, 56 no change in area density in frontal and parietal cortex but increased area density in parahippocampal cortex, 22 and no change in area density averaged across neocortical and medial temporal regions have been reported. 57 These earlier studies were limited as a group, as they did not control for the presence of Lewy Body pathology and also because they did not correct for multiple comparisons and/or account for the within-subject correlation of severity of neuropathology across brain regions (see Sweet et al 20 for a discussion of these issues).
Two studies recently redressed these latter limitations. Sweet et al 20 examined semiquantitative area density of neuritic plaques and neurofibrillary tangles in six brain regions: middle frontal cortex, hippocampus, inferior parietal cortex (IPC), superior temporal cortex, occipital cortex, and transentorhinal cortex in 24 AD þ P subjects and 25 AD subjects without psychosis. The groups were matched on clinical characteristics and on the presence of Lewy Body pathology. There were no significant associations between neuritic plaque and neurofibrillary tangle severity and AD þ P, and no significant associations with any individual psychotic symptom. Farber et al 21 examined 69 AD þ P and 40 AD subjects without psychosis. A significant association between AD þ P and increased neurofibrillary tangle area density was found, but limited to select heteromodal neocortical regions (middle frontal, superior temporal, and inferior parietal). In contrast, in the medial temporal lobe structures examined, no increase in neurofibrillary tangle area density was found. The associations were not altered after accounting for comorbid Lewy Body pathology. No association with increased area density of senile plaques was found. The discrepancy between these results is not readily explained, though it remains possible that some cases of AD þ P do result from neurofibrillary pathology.
Another consideration results from recent neuropathologic data that suggests that Lewy body pathology may be far more frequent than previously realized in neuropathologically confirmed AD. 47 The presence of well-formed visual hallucinations and delusions are among the criteria for the clinical diagnosis of DLBs. In subjects with a neuropathologic diagnosis of AD, however, post-mortem evidence of concurrent cortical Lewy body pathology has only inconsistently been associated with AD þ P. 58 Whether the presence of psychotic symptoms in AD may be related to regional severity of superimposed Lewy Body 43, 46 pathology has not been examined.
If there is little evidence to indicate that AD þ P arises as an epiphenomenon of more advanced AD, is there evidence of a specific biologic process that might contribute to the genesis of psychotic symptoms and more severe cognitive impairment? Emerging evidence suggests that AD þ P is associated with neocortical dysfunction in excess of that seen in AD without psychosis. Functional imaging studies in vivo have found AD þ P subjects to demonstrate excess impairment of frontal, temporal, and parietal cerebral blood flow and glucose metabolism in comparison to AD subjects without psychosis. 59, 60 We recently examined post-mortem magnetic resonance spectroscopy in AD þ P subjects, finding significant reductions in neocortical N-acetyl-L-aspartate (NAA, a marker of neuronal integrity) concentrations, with superior temporal gyrus, dorsolateral prefrontal cortex, and inferior parietal cortex most affected. 61 AD þ P subjects also demonstrated significant elevations in concentrations of the phosphodiester membrane breakdown product, glycerophosphoethanolamine, in comparison to AD subjects without psychosis. It is noteworthy that similar observations have been emerging in the study of idiopathic psychosis in subjects with schizophrenia. In vivo These in vivo findings may reflect the reductions in neocortical pyramidal cell volume [63] [64] [65] and synaptic markers [66] [67] [68] [69] seen in post-mortem studies of subjects with schizophrenia. These congruent findings raise the hypothesis that factors effecting neocortical neuronal and synaptic integrity and number, and their genetic determinants may contribute to psycho-sis in both disorders, though the obvious differences in the neuropathology of AD and schizophrenia suggest that the specific pathologic mechanisms may not overlap.
Familial aggregation and heritability of AD þ P A multigenerational early onset familial non-AD dementia with prominent schizophreniform psychosis has been described. 70 We are not aware of similar reports in AD. However, there is emerging evidence that AD þ P is more prevalent among the affected siblings of AD þ P probands than among the affected siblings of AD subjects without psychosis. Tunstall et al 71 examined 99 sibling pairs concordant for AD and found a concordance rate of 0.21 for AD þ P. This rate of concordance was moderately higher than that predicted by the observed prevalence of 0.41 of AD þ P in their cohort, though no statistical tests of significance were reported. Sweet et al recently examined the familial risk of AD þ P in a larger cohort of 371 AD probands and 461 of their siblings also diagnosed with AD, recruited and characterized as part of the National Institutes of Mental Health AD Genetics Initiative. 6 There was a significant association between proband psychosis status and the occurrence of AD þ P in siblings. After fitting a GEEbased logit model with dementia stage entered as a covariate, the estimated Odds Ratio (OR) for AD þ P in siblings of AD þ P probands was 2.41 (95% CI: 1.46 -4.00; P o 0.001) in comparison to the siblings of nonpsychotic AD probands. Using a more restrictive definition of AD þ P strengthened the observed association (OR 3.18; CI: 2.17 -4.66; P o 0.0001). The association was unaltered when sibling age, and sibling age-of-onset of AD, or presence of extrapyramidal symptoms were entered as covariates in the analysis. Increased risk of a similar magnitude was also seen when analyses were limited to siblings diagnosed only with definite or probable AD. It is not known if the morbid risk for AD þ P is also increased among the other relatives of AD þ P probands. Nor have twin studies of AD þ P been reported, and thus the degree of contribution to the observed familial aggregation of AD þ P from genetic and from environmental sources cannot yet be estimated.
Cosegregation of AD þ P and idiopathic psychoses
If genetic factors underlying idiopathic psychoses (eg schizophrenia) increase susceptibility for AD þ P, an increased morbid risk for idiopathic psychoses could be expected among relatives of AD þ P probands. Clinical experience and limited data suggest that a family history of major psychiatric illness is not more frequent in AD þ P than in AD subjects without psychosis. Gilley et al 72 found no increase in family history of psychiatric illness in 67 AD subjects with hallucinations in comparison to 137 AD subjects without hallucinations. Similarly, Kotrla et al 73 found no increase in family history of schizophrenia in 36 AD þ P subjects in comparison to 21 nonpsychotic AD subjects. These studies were limited, however, by small sample sizes and an absence of structured diagnostic interviews of multiple family members.
Conversely, it is not known if there is an increased rate of AD þ P in families of subjects with schizophrenia or other idiopathic psychoses. There is strong evidence, however, that even among subjects with schizophrenia who have evidence of dementia, AD pathology is rare. 74 Possible genetic models of AD + P Several possible pathways by which genetic factors may lead to AD þ P are presented in Figure 1 . We have previously proposed the presence of disease modifying genes that lead to AD þ P in individuals who develop AD due to other genetic and environmental influences, as illustrated in Pathway A1. 5 This pathway is consistent with certain findings discussed Figure 1 Pathways to AD and AD þ P. In Pathway A1, alleles at modifier genes lead to AD þ P after onset of AD, which is due to distinct genetic and environmental influences. Some of these disease-modifying alleles could also modify the course of other neurodegenerative (Pathway A2) or neurodevelopmental (Pathway A3) illnesses, contributing to psychosis risk in these conditions. In Pathway B, alleles at genes that increase the liability to onset of AD would also increase the risk for AD þ P. In Pathway C, alleles contributing major risk for idiopathic psychoses such as schizophrenia would be seen to also contribute to AD þ P risk. See text (section Possible genetic models of AD þ P) for additional details regarding existing data supporting or contradicting the proposed pathways.
above: AD þ P is rare as a prodrome of AD, and occurs with increasing frequency as individuals traverse the early and middle disease stages. Some of these disease modifying genes may modify the course of other neurodegenerative (Pathway A2) or neurodevelopmental (Pathway A3) illnesses, contributing to psychosis risk in these conditions. 5 In Pathway B, genes that increase the liability to onset of AD would increase risk for AD þ P. In Pathway C, genes contributing major risk for idiopathic psychoses such as schizophrenia would be seen to also contribute to AD þ P risk.
Initial studies conducted in unrelated AD þ P and AD without psychosis subjects have found associations of candidate genes consistent with this model. Polymorphic variation in the genes for the dopamine 1 and dopamine 3 receptors (DRD1 and DRD3), 5,75 the serotonin 2A and serotonin 2C receptors (HTR2A and HTR2C), 76 and long alleles of the serotonin transporter gene (HTT or SLC6A4), 26 have been found to confer moderate, but significant, increases in risk for AD þ P. One of these, DRD3, has also been associated with a small but significant increase in the risk of schizophrenia in both case-control and family studies. 77 These findings are most consistent with a disease-modifying gene (Pathway A), though Pathway C cannot be excluded.
Recently, using publicly available genome scan data from the NIMH AD Genetics Initiative, 3, 78 we conducted the first linkage analysis of AD þ P in individuals with LOAD. 79 Genome-wide multipoint linkage analysis was performed in families with two or more individuals with LOAD þ P. In our principal analysis, we focused on Pathway A1. Since the most important identified genetic risk factor for LOAD is the presence of one or more e4 alleles for the apolipoprotein E gene (APOE4), we restricted analysis to the 42 families in which at least two individuals also had one or more e4 alleles (LOAD þ P þ e4 families). In our secondary analysis, we examined all 65 LOAD þ P families (Pathway A and/or Pathway B). To evaluate the results of the linkage analysis, we performed extensive simulations, which yielded critical values for genome-wide significant and suggestive linkage of 3.18 and 1.70, respectively. Linkage analysis of LOAD þ P þ e4 families revealed one significant and two suggestive linkages: MLS ¼ 3.52 on 2p, near D2S1356; MLS ¼ 2.01 on 6q, near marker D6S1021; and MLS ¼ 1.94 on 21q, at D21S1440. Linkage analysis of LOAD þ P families yielded one suggestive linkage, MLS ¼ 2.51, at the same 6q location as the linkage signal from the LOAD þ P þ e4 families.
The suggestive linkage on Chromosome 6q for the LOAD þ P þ e4 sample, and in the total LOAD þ P sample, was more distal from the best linkage signal produced by prior linkage analysis of AD cohorts. 3, 80 The significant linkage signal on Chromosome 2p, produced by analysis of LOAD þ P þ e4 families, has no equivalent finding in the AD literature aside from the original Kehoe study, which reported an MLS peak of 1.01 at the same location for e4 positive families. Interestingly, some support for both the 2p and the 6q region can be garnered from the schizophrenia literature. [81] [82] [83] [84] While this concurrence of findings in schizophrenia and LOAD þ P provides some support for the presence of common psychosis genes (Pathways A and C), cautious interpretation is still required. Despite the common psychosis phenotype, there are substantial clinical and neurobiological differences between the two disorders, and the chromosomal region in which linkage has been detected in these two conditions is broad.
In Pathway B, genes that increase the liability to onset of AD would increase risk for AD þ P. For example, a familial frontotemporal dementia in which affected individuals often present with a schizophreniform psychosis has been reported. 70 We are unaware, however, of reports of similar pedigrees for AD þ P. A number of investigations have examined whether APOE4 might contribute to the AD þ P phenotype. While one large and two smaller studies have found an association of APOE and AD þ P, [85] [86] [87] most reports have found no association of APOE4 with AD þ P. 33, [88] [89] [90] [91] [92] [93] Furthermore, though the major effect of APOE4 on AD phenotype is to reduce age-ofonset of AD, 94 APOE4 genotype is not associated with reduced time to onset of AD þ P. 95 Nor was association of increased risk for AD þ P with the putative AD risk gene, alpha-1-antichymotrypsin (ACT) detected. 95 Similarly, there is no evidence that any of the risk genes found to be associated with AD þ P in casecontrol studies (see above) also contribute to AD risk. Though some, 96, 97 but not all, 98 studies have found an association of AD with short alleles of a 44 bp insertion/deletion polymorphism in the 5 0 promoter region of HTT, it was the presence of long alleles that was associated with increased AD þ P risk. 26 In Pathway C, genes contributing major risk for idiopathic psychoses such as schizophrenia would be seen to also contribute to AD þ P risk. In this scenario, an increased morbid risk for schizophrenia would be anticipated in the families of AD þ P probands, and an elevated risk for AD þ P would also be anticipated in a subgroup of subjects with schizophrenia or in their family members. Though data are limited, families of AD þ P probands do not appear to have an increased frequency of syndromal psychosis. 72 We are not aware of data informing whether families of schizophrenia probands have an increased morbid risk of AD þ P, though there is compelling evidence that AD is rare in subjects with schizophrenia. 73, 74 Thus, most data presently available are consistent with Pathway A. Definitive discrimination between these genetic models of AD þ P, however, is not possible at this time, leaving open the possibility that multiple pathways are operative.
Limitations and future investigative strategies Though the above review provides substantial evidence in support of the hypothesis that psychotic symptoms define a suitable subphenotype in AD patients for gene-mapping efforts, several limitations persist. We have focused on psychotic symptoms as the clinical marker for this phenotype. Most individuals diagnosed with AD, however, will experience several behavioral disturbances. Exclusive focus on psychotic symptoms as the defining element may exclude other important accessory symptoms. Similarly, a psychosis phenotype may best be defined by the interaction between the presence of the defining symptoms and the timing of their emergence during the illness course, that is AD þ P onset in early illness may define a different phenotype than AD þ P onset in late illness. Finally, psychosis may be merely an epiphenomena or marker of the true underlying endophenotype, which may itself be more directly defined by a specific pattern or rate of change of cognitive deficits, or by an additional neuropathologic process such as the presence of Lewy Bodies. These limitations suggest several areas of future study to further refine the AD þ P phenotype that may augment both neurobiologic and genetic studies of AD þ P.
It is unknown if the biologic substrate leading to AD þ P does so in a quantitative manner, or if there is a threshold which, when exceeded, leads to AD þ P. Prior genetic studies of AD þ P have treated AD þ P as a dichotomous variable, in essence adopting the latter model. However, if AD þ P can be modeled as a quantitative trait, additional genetic analysis methods can be brought to bear on the examination of AD þ P. For example, methods for linkage analyses of affected sibling pairs utilizing covariates have recently been developed. [99] [100] [101] Covarying for psychosis may lead to new or refined findings in linkage analysis of AD proper. A quantitative psychosis trait would also allow for the possibility of QTL modeling of genome scan data for novel psychosis loci, though issues of sample size may constrain the value of this approach. 102, 103 Finally, with the development of highthroughput genotyping methods, and the availability of analytic approaches such as genomic control that can enhance the utility of association analysis, 104 the use of a quantitative trait may increase the power to detect the association of AD þ P with candidate gene loci. These efforts will require clinical studies that categorize the frequency and persistence of specific psychotic symptoms in individuals with AD. Several different approaches to quantifying psychotic symptoms might be used: number of psychotic symptoms endorsed, frequency of occurrence of individual psychotic symptoms, time to onset of psychotic symptoms, persistence of psychotic symptoms over time, presence of other behavioral symptoms and combinations of these aspects. Other aspects of the psychotic symptoms such as treatment responsiveness may also be informative. Even if modeling a quantitative psychosis trait is unsuccessful, such studies should inform the appropriate threshold (or cutpoint) to use in classifying someone as AD þ P.
Improved characterization of the AD þ P phenotype would also result from evaluation of possible subtypes. AD þ P may be a composite of several biologically, and genetically, relevant phenotypes. We have previously demonstrated that the presence of aggressive behavior, which occurs in approximately half of AD þ P subjects, defines a subphenotype more strongly associated with long alleles for the serotonin transporter (HTT) promoter polymorphism than AD þ P alone. 26 Similarly, misidentification delusions, paranoid delusions, auditory and visual hallucinations may identify subgroups within AD þ P with distinct neurobiologic and genetic determinants. 76 Evaluating the independence and longitudinal stability of these symptom clusters in AD þ P should improve the ability to detect biologically relevant associations, including clinical-pathologic correlations with regional severity of neuropathologic markers. Identified subphenotypes might also be quantitative traits, with the advantages for linkage and association analysis described above.
Finally, firmly establishing the genetic basis of AD þ P would be furthered by additional familial studies addressing the heritability and cosegregation of AD þ P. This may require de novo characterization of families, with attention both to adequately detailed cataloging of the psychotic symptoms present in subjects with AD and to a detailed assessment of minor psychotic symptoms in unaffected family members. Such a sample would be appropriate for application of linkage analysis in an effort to identify contributory genes. Studies of AD þ P in monozygotic vs dizygotic twins would also be valuable.
Summary
Psychotic symptoms are reliably identified in AD patients. The presence of AD þ P appears to identify a clinically significant syndrome with more rapid cognitive and functional deterioration, and a greater liability to aggressive behavior. Multiple studies indicate at least moderate state independence of AD þ P. Thus, while AD þ P typically does not become apparent in an individual until the middle stages of AD, it tends to be persistent. The available evidence suggests that AD þ P reflects a biologically specific process, and is not merely an epiphenomenon of AD. If there is an association of AD þ P with the severity of neuropathologic lesions of AD, it appears to be modest. There is emerging evidence of familial aggregation of AD þ P. Significant findings from candidate gene association studies and initial linkage analyses are encouraging. Future efforts will benefit from the collection of new cohorts of families, with detailed behavioral characterizations. If the specific genetic factors contributing to AD þ P can be identified, they may provide leads to the understanding of mechanisms of psychosis and cognitive impairment.
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